Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has been assigned a $3.00 price target by equities researchers at B. Riley in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price target points to a potential upside of 334.78% from the company’s current price.
ATNM has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Maxim Group initiated coverage on Actinium Pharmaceuticals in a research note on Thursday, September 14th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, Roth Capital restated a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd.
Shares of Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.69 on Tuesday. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72.
COPYRIGHT VIOLATION NOTICE: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://transcriptdaily.com/2017/12/12/actinium-pharmaceuticals-atnm-pt-set-at-3-00-by-b-riley.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.